| PRODUCT | DETAILS |
|---|---|
| Sintilimab | — |
| Bevacizumab Biosimilar | — |
| Mazdutide | — |
| IBI362 | — |
China's leading PD-1 innovator. Sintilimab (Tyvyt) is one of China's top-selling PD-1 inhibitors, developed in partnership with Eli Lilly for global rights. Expanding into metabolic disease with mazdutide (GLP-1/glucagon dual agonist) competing in the obesity space. HKEX-listed only (1801.HK).